Dr. Kim Chi, Senior Research Scientist, Vancouver Prostate Centre discusses his presentation at ESMO 2023, abstract #LBA85 – Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE.
Senior Research Scientist, Vancouver Prostate Centre
Chief Medical Officer & Vice President, BC Cancer
Medical Oncologist, BC Cancer – Vancouver
Professor, Department of Medicine, UBC
Dr. Chi is a medical oncologist with BC Cancer who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research.
Dr. Chi’s research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs. This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He has had peer reviewed grant funding for the conduct of early phase clinical trials and associated correlative studies from the Canada Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute, The U.S. Department of Defense, the Prostate Cancer Foundation (USA), Movember and Prostate Cancer Canada. Nationally and internationally he has led a number of multi-centre Phase I, II and III clinical trials including cooperative group studies and investigator sponsored studies with agents sourced from the US National Cancer Institute’s Cancer Therapy Evaluation Program (NCI CTEP) and industry collaborators. He has led the phase I through III development of two novel compounds (OGX-011 and OGX-427), which came from academic preclinical development at the Vancouver Prostate Centre. He has also contributed to clinical trials that established new standard of care for patients with advanced prostate cancer (docetaxel, abiraterone acetate, enzalutamide).
On July 1, 2019, Dr. Chi was appointed Vice President and Chief Medical Officer, BC Cancer. Prior to this, he was the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre. He was appointed Chair of the Genitourinary Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at www.bccancer.bc.ca) and securing access to new therapies through the province’s health care system. Under his guidance as medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre (which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies), the not-for-profit Clinical Trials Unit almost doubled patient accrual to trials, becoming a self-sustaining growth operation.
Dr. Chi is Professor with the Department of Medicine at the University of British Columbia. He is also the Co-Chair of the Genitourinary Disease Site for the Canadian Cancer Trials Group (CCTG) and the Canadian Uro-Oncology Group, which is responsible for developing the genitourinary cancer trials undertaken by investigators at a national cooperative group level. In addition, he is an Executive Committee Member and Past-Chair of the Investigational New Drug Site for the CCTG, which is responsible for developing early phase I/II trials across the CCTG disease sites.